Welcome!

News Feed Item

Twice as Many People Think Cancer is a Death Sentence in the UK Compared to the US

BASINGSTOKE, England, August 23, 2013 /PRNewswire/ --

New research sheds light on UK public perceptions about cancer care

The Lilly PACE initiative this week launched the results of a survey of cancer patients, their carers and the general public around current perceptions of cancer care.

The survey, conducted in six countries across the globe, showed that in the UK although the majority of people (73%)[1] are satisfied with recent progress in the fight against cancer, half of them (42%)[1] still feel a diagnosis of cancer is a death sentence. This was double the percentage reported by American survey respondents, suggesting people in the UK have lower expectations of cancer treatment.[1]

In addition, 70%[1] of people believe current challenges facing the UK economy could stifle innovative cancer research, with a strong majority (74%)[1] believing it takes too long for new cancer medicines to reach patients. This may be a legitimate concern. In 2012 an Office of Health Economics report showed that the median time it took a newly launched drug to receive publication of NICE guidance via the Single Technology Appraisal process was over two and a half years.[2]

In the UK there was also concern about resources, with almost half (48%)[1] of those questioned believing not enough is being spent on cancer research. In addition, 72% of the general population, 87% of patients and 81% of carers think that the NHS should pay for life-prolonging treatment.[1] With the Government set to change the way drugs in the UK are priced within the next six months and NICE playing a key role in assessing medicines for funding, these are important findings about the public views. Furthermore, the Cancer Drugs Fund, used to pay for life prolonging treatments in oncology, is due to end soon.

Describing the PACE Cancer Perceptions Index, Andrew Wilson (Rarer Cancers Foundation) explained: "It is shocking to see that such a large proportion of people still see cancer as a death sentence. It is essential that the recent changes to the NHS, uncertainty over the future of the Cancer Drugs Fund and changing in drugs pricing do not represent hurdles for patients or delay their access to innovative cancer medicines. Research such as this highlights why improving cancer management should continue to be an area of government focus."

The PACE Cancer Perceptions Index also showed around half (56%)[1] of the UK public understood that incremental "small-step" advances in treatment for cancer, rather than blockbuster developments, are integral to progress when it comes to treating and managing the disease. The research also reveals how those involved in the development of cancer medicines are perceived, with pharmaceutical companies recognised as equal to academic researchers in advancing cancer treatments.

Describing the PACE Cancer Perceptions Index, Dr Mick Peake, Consultant and Senior Lecturer in Respiratory Medicine, Clinical Lead, National Cancer Intelligence Network, and Chair of the UK PACE advisory board, explained: "Step by step we are continuing to gain ground in the fight against cancer and it's great that people in the UK understand this.  However, it's important not to lose momentum especially given that our cancer survival rates lag behind many other European countries. We must build on our successes in order to make progress and, despite the slowdown in the UK economy, it is essential that steps are put into place to speed up and give patients greater access to excellence in cancer care and treatment."

Notes to editors:

About PACE

PACE stands for Patient Access to Cancer care Excellence. Created by Lilly Oncology as a global collaboration spanning diverse sectors, PACE exists to encourage public policies and health care decisions that speed the development of new medicines, promote rapid learning from patient experiences and assure that cancer care and treatment responds to the needs and qualities of individual patients. The PACE programme believes that by putting patients at the centre of cancer care we will ensure access to excellence and innovation in treatment.

About the PACE Cancer Perceptions Index

The Lilly PACE study was fielded in the UK, France, Germany, Italy, Japan, and the United States. Three respondent groups were interviewed in each country: general population, cancer patients, and cancer patient caregivers.

The survey of over 4000 people around the world included over 700 UK respondents.

All respondents in all sample groups were required to be 18 years of age or older in order to participate. Patients were screened for a cancer diagnosis in the past 5 years, having undergone at least one of the following treatments: surgery, chemotherapy (or infusional injections or oral anti-cancer drugs), or radiation therapy. The same requirements pertained to the person caregivers were helping and about whom they were responding. Data were monitored during the field period to make certain that there was a mix of different types of the most prevalent cancers. The results yielded a mix of cancers naturally. The cancers that were monitored were breast, lung, colon, and prostate.

About Lilly Oncology

For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer and because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. Lilly has a strong heritage in oncology and has a history of developing treatments for lung, ovarian, breast and pancreatic cancer and mesothelioma

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers-through medicines and information-for some of the world's most urgent medical needs.

About Lilly UK

Lilly UK is the UK Affiliate of Eli Lilly and Company. Lilly has been operating in the UK since 1934 and employs approximately 1400 people throughout the country working in sales and marketing, research and development and bio-tech manufacturing.

1. Data on file. Eli Lilly and Company and/or one of its subsidiaries.

2. Phill O'Neill, Nancy Devlin and Ruth Puig-Peiró. Time Trends in NICE HTA Decisions. Office of Health Economics. Jan 2012. http://www.ohe.org/publications/article/time-trends-in-nice-hta-decisions-107.cfm (website accessed Aug 2013)

Contact:

Jim Baxter
Tel: +44-(0)20-7400-4480
Mobile: +44-(0)7900-605-652
Email: [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Customer experience has become a competitive differentiator for companies, and it’s imperative that brands seamlessly connect the customer journey across all platforms. With the continued explosion of IoT, join us for a look at how to build a winning digital foundation in the connected era – today and in the future. In his session at @ThingsExpo, Chris Nguyen, Group Product Marketing Manager at Adobe, will discuss how to successfully leverage mobile, rapidly deploy content, capture real-time d...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
IoT generates lots of temporal data. But how do you unlock its value? How do you coordinate the diverse moving parts that must come together when developing your IoT product? What are the key challenges addressed by Data as a Service? How does cloud computing underlie and connect the notions of Digital and DevOps What is the impact of the API economy? What is the business imperative for Cognitive Computing? Get all these questions and hundreds more like them answered at the 18th Cloud Expo...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, will explore the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences betwee...
As cloud and storage projections continue to rise, the number of organizations moving to the cloud is escalating and it is clear cloud storage is here to stay. However, is it secure? Data is the lifeblood for government entities, countries, cloud service providers and enterprises alike and losing or exposing that data can have disastrous results. There are new concepts for data storage on the horizon that will deliver secure solutions for storing and moving sensitive data around the world. ...
Enterprise networks are complex. Moreover, they were designed and deployed to meet a specific set of business requirements at a specific point in time. But, the adoption of cloud services, new business applications and intensifying security policies, among other factors, require IT organizations to continuously deploy configuration changes. Therefore, enterprises are looking for better ways to automate the management of their networks while still leveraging existing capabilities, optimizing perf...
What a difference a year makes. Organizations aren’t just talking about IoT possibilities, it is now baked into their core business strategy. With IoT, billions of devices generating data from different companies on different networks around the globe need to interact. From efficiency to better customer insights to completely new business models, IoT will turn traditional business models upside down. In the new customer-centric age, the key to success is delivering critical services and apps wit...
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
The essence of data analysis involves setting up data pipelines that consist of several operations that are chained together – starting from data collection, data quality checks, data integration, data analysis and data visualization (including the setting up of interaction paths in that visualization). In our opinion, the challenges stem from the technology diversity at each stage of the data pipeline as well as the lack of process around the analysis.
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
Cloud-based NCLC (No-code/low code) application builder platforms empower everyone in the organization to quickly build applications and executable processes that broaden access, deepen collaboration, and enhance transparency for all team members. Line of business owners (LOBO) and operations managers know best their part of the business and their processes. IT departments are beginning to leverage NCLC platforms to empower and enable LOBOs to lead the innovation, transform the organization, an...
@DevOpsSummit taking place June 7-9, 2016 at Javits Center, New York City, and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
SYS-CON Events announced today that ContentMX, the marketing technology and services company with a singular mission to increase engagement and drive more conversations for enterprise, channel and SMB technology marketers, has been named “Sponsor & Exhibitor Lounge Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York. “CloudExpo is a great opportunity to start a conversation with new prospects, but what happens after the...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device. For more information, please visit https://www.mangoapps.com/.
SYS-CON Events announced today the Docker Meets Kubernetes – Intro into the Kubernetes World, being held June 9, 2016, in conjunction with 18th Cloud Expo | @ThingsExpo, at the Javits Center in New York, NY. Register for 'Docker Meets Kubernetes Workshop' Here! This workshop led by Sebastian Scheele, co-founder of Loodse, introduces participants to Kubernetes (container orchestration). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, participants learn ...